Remove Clinical Trials Remove Life Science Remove Medicine Remove Trials
article thumbnail

Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. 134

XTalks

Allergan Aesthetics is focused on creating products and technologies that drive the advancement of aesthetic medicine. Dr. Manson Brown’s Clinical Development and Scientific Innovation team are responsible for global clinical trial development strategy for the Aesthetic Medicine portfolio, covering pharmaceuticals and device.

article thumbnail

AI and machine learning: A new era for clinical trials

Drug Discovery World

Fiona Maini , Senior Director Global Compliance & Strategy, at Medidata looks at the rise of artificial intelligence (AI) and machine learning (ML) within life sciences and the applications for the technology in clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clinical Trials For All Campaign: Converging Trials and Healthcare

XTalks

Recruiting participants is perhaps the most challenging aspect of any clinical trial, regardless of the therapeutic area. Yet this one piece is also the most vital, with a trial’s ability to enroll and retain participants being a key predictor of a study’s future success. What is Clinical Trials For All?

article thumbnail

What Are the Top Oncology Clinical Trial Trends Through the Lens of ESMO?

XTalks

Given this hotbed of activity, innovation in the space to drive faster decisions and more efficient trials is intense. They discussed the top new trends in oncology trial design that sponsors are either incorporating into clinical trials or need to start planning to include.

article thumbnail

Cell Therapies for Chronic Kidney Disease: Featuring Bruce Culleton, CEO, ProKidney – Xtalks Life Science Podcast Ep. 153

XTalks

Before beginning his career in industry in 2007, Dr. Culleton was a Clinical Associate Professor in the Department of Medicine at the University of Calgary. The candidate is currently being evaluated in Phase II and Phase III clinical trials. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

In conversation with FNIH’s Dr. Courtney Silverthorn, Director of the AMP Bespoke Gene Therapy Consortium, About New Rare Disease Trial Portfolio – Xtalks Life Science Podcast Ep. 114

XTalks

Courtney Silverthorn who is an Associate Vice President at the Foundation for the National Institutes of Health (FNIH) and the Director of the Accelerating Medicines Partnership (AMP) program including the Bespoke Gene Therapy Consortium. Xtalks spoke with Dr. Silverthorm about the consortium’s new rare disease clinical trial portfolio.

article thumbnail

Improving Black Participation in Clinical Trials: Bridging the Gap

XTalks

Black participation in clinical trials, and the underrepresentation of minority groups in general in trials, remains low. It is therefore important to work towards increasing Black participation in clinical trials, which begins with understanding the barriers to participation and taking steps to address them.